Sharon Bio-Medicine has soared 16% to Rs 428, extending its Monday’s around 5% gain, after the company announced that holders of the foreign currency convertible bonds (FCCBs) approved the company's proposal for an extension of maturity date till February 28, 2013.
“The FCCBs trustee has received a “Written Resolution” from the bondholders holding in aggregating $15.6 million accounts 95% in principle amount of bonds from the total $16.5 million that the bondholders have agreed to extend the date for negotiation for conversion/redemption or rollover of the FCCB which were due on December 4, 2012 to February 28, 2013,” Sharon Bio-Medicine said in a statement.
The stock opened at Rs 372 and hit a high of Rs 440 on the NSE. As many as a combined 40,129 shares have already changed hands on the counter till late noon deals against an average around 20,000 shares that were traded daily in past two weeks.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
